Natera Earlier Announced Updated Data From CIRCULATE-Japan Presented At ESMO 2023 Reinforces Signatera's Prognostic And Predictive Value In Analysis of 2,500+ Colorectal Cancer Patients
Portfolio Pulse from Charles Gross
Natera, Inc. (NASDAQ:NTRA) announced updated data from the GALAXY arm of the CIRCULATE-Japan trial, reinforcing the prognostic and predictive value of the Signatera molecular residual disease (MRD) test in colorectal cancer patients. The updated data builds on published evidence with twice as many patients and disease-free survival data extended to 24 months.
October 22, 2023 | 10:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's updated data from the CIRCULATE-Japan trial could potentially increase the demand for the Signatera MRD test, which may positively impact Natera's stock price.
The updated data from the CIRCULATE-Japan trial reinforces the value of Natera's Signatera MRD test in colorectal cancer patients. This could potentially increase the demand for the test, leading to increased revenues for Natera and a potential rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100